Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Vaccines

Free Subscription 13.10.2025 1 Arch Pediatr 1 Arch Virol 2 BMJ 9 Clin Infect Dis 2 J Gen Virol 1 J Infect 1 J Infect Dis 2 J Virol 1 JAMA 1 Lancet 1 N Engl J Med 3 Nat Med 1 Pediatr Infect Dis J 1 PLoS One 33 Vaccine

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Arch Pediatr

1. RAKOCZY K, Kaczor J, Soltyk A, Mastalska I, et al
   Vaccinating children against SARS-CoV-2 - parents' attitude.
   Arch Pediatr. 2025 Oct 8:S0929-693X(25)00139.
   PubMed         Abstract available
   
   

   
   Arch Virol

2. RYU NG, Yang YJ, Kim KI
   Application of a multi-epitope DNA vaccine against viral hemorrhagic septicemia virus type ?a.
   Arch Virol. 2025;170:222.
   PubMed        
   
   

   
   BMJ

3. WISE J
   Covid-19: Excluding doctors from vaccination programme puts patients at risk, clinicians warn.
   BMJ. 2025;391:r2141.
   PubMed        
   
   
4. TANNE JH
   Acting CDC director calls for MMR break-up in overhaul of US vaccine schedule.
   BMJ. 2025;391:r2130.
   PubMed        
   
   

   
   Clin Infect Dis

5. BELSHE RB, Bernstein DI, Edwards KM, Frey SE, et al
   Vaccine and Treatment Evaluation Units: A Historical Perspective.
   Clin Infect Dis. 2025;81.
   PubMed         Abstract available
   
   
6. JANO K, Babu TM, Kottkamp AC, Rebolledo PA, et al
   Historical Advances in Clinical Trial Design and Expanding Representation as the New Frontier for Innovation.
   Clin Infect Dis. 2025;81.
   PubMed         Abstract available
   
   
7. DOBRZYNSKI DM, Graciaa DS, Babu TM, Coler RN, et al
   From Yesterday to Tomorrow: How Vaccine Platforms Have Shaped the Vaccine and Treatment Evaluation Units.
   Clin Infect Dis. 2025;81.
   PubMed        
   
   
8. WHITAKER JA, Collins MH, Rebolledo PA, Dobrzynski D, et al
   Future Goals and Long-term Vision of the Infectious Diseases Clinical Research Consortium/Vaccine and Treatment Evaluation Unit Network.
   Clin Infect Dis. 2025;81.
   PubMed         Abstract available
   
   
9. ATMAR RL, Abate G, Deming ME, George SL, et al
   Emerging and Pandemic Pathogens: Lessons Learned From a Clinical Research Network.
   Clin Infect Dis. 2025;81.
   PubMed         Abstract available
   
   
10. ERBELDING EJ, Marrazzo JM
    Vaccine Treatment and Evaluation Units: Why Support a "Ready Base" of Clinical Trial Sites?
    Clin Infect Dis. 2025;81.
    PubMed         Abstract available
    
    
11. BELONGIA EA, Nguyen HQ, McClure DL, Lewis N, et al
    Approaches to Comparing Influenza Vaccine Effectiveness to Guide Potential Preferential Product Recommendations.
    Clin Infect Dis. 2025 Oct 9:ciaf563. doi: 10.1093.
    PubMed         Abstract available
    
    
12. PONCE D, Westercamp M, Soto G, Lessa FC, et al
    COVID-19 Exposure, Protective Measures, Symptom Assessment, and Risk Perception Among Healthcare Workers in Peru: A Longitudinal Cohort Study (2020-2021).
    Clin Infect Dis. 2025 Jul 29:ciaf343. doi: 10.1093.
    PubMed         Abstract available
    
    
13. STAFFORD E, Dimitrov D, Trinidad SB, Matrajt L, et al
    Closing the Gap in Race-based Inequities for Seasonal Influenza Hospitalizations: A Modeling Study.
    Clin Infect Dis. 2025;81:478-487.
    PubMed         Abstract available
    
    

    
    J Gen Virol

14. PFRANGER M, Krause N, Asbach B, Meier J, et al
    Immunogenicity of a trivalent haemorrhagic fever vaccine candidate against Sudan virus, Marburg virus and Lassa virus in an mpox vaccine.
    J Gen Virol. 2025;106:002157.
    PubMed         Abstract available
    
    
15. DVORAK M, Arbon D, Salat J, Fortova A, et al
    Sex-dependent impairment of antibody responses to tick-borne encephalitis virus vaccination and infection in obese mice.
    J Gen Virol. 2025;106:002161.
    PubMed         Abstract available
    
    

    
    J Infect

16. MAZZOTTA V, Matusali G, Cimini E, Caioli A, et al
    Corrigendum to "Humoral and T-cell responses following MVA-BN booster vaccination against mpox virus clades Ib and IIb" [J Infect 91 (2025) 106602].
    J Infect. 2025;91:106631.
    PubMed        
    
    

    
    J Infect Dis

17. KASAI M, Nakano S, Koide S, Otake S, et al
    Prevalence of candidate vaccine targets and genomic features of pediatric invasive Streptococcus agalactiae in Japan.
    J Infect Dis. 2025 Oct 9:jiaf491. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Virol

18. LAI DC, Nguyen TN, Trinh GP, Steffen D, et al
    Lipid nanoparticle-encapsulated DNA vaccine induces balanced antibody and T-cell responses in pigs with maternally derived antibodies.
    J Virol. 2025 Oct 9:e0112325. doi: 10.1128/jvi.01123.
    PubMed         Abstract available
    
    
19. BESSEY TK, Wang Y, Moon S-S, Sanchez-Tacuba L, et al
    Mutations of two amino acids in VP5 mediate the attenuation of human rotavirus vaccine: evidence from in vitro and in vivo studies.
    J Virol. 2025 Oct 8:e0106725. doi: 10.1128/jvi.01067.
    PubMed         Abstract available
    
    

    
    JAMA

20. ANDERER S
    As Measles Cases Climb in the Americas, Vaccination Urged.
    JAMA. 2025 Oct 10. doi: 10.1001/jama.2025.17493.
    PubMed        
    
    

    
    Lancet

21. HENDRICK J, Raqib R, Noor Z, Faruque ASG, et al
    Shigellosis.
    Lancet. 2025;406:1508-1519.
    PubMed         Abstract available
    
    

    
    N Engl J Med

22. CAI M, Xie Y, Al-Aly Z
    Association of 2024-2025 Covid-19 Vaccine with Covid-19 Outcomes in U.S. Veterans.
    N Engl J Med. 2025 Oct 8. doi: 10.1056/NEJMoa2510226.
    PubMed         Abstract available
    
    

    
    Nat Med

23. KAMPMANN B, Hucko A
    Ebola vaccine safe for mothers and infants.
    Nat Med. 2025 Oct 9. doi: 10.1038/s41591-025-04000.
    PubMed        
    
    
24. CHEN WH, Barnes RS, Sikorski MJ, Datar R, et al
    A combination typhoid and non-typhoidal Salmonella polysaccharide conjugate vaccine in healthy adults: a randomized, placebo-controlled phase 1 trial.
    Nat Med. 2025 Oct 8. doi: 10.1038/s41591-025-04003.
    PubMed         Abstract available
    
    
25. NAIR NP, Reddy SN, Giri S, Thiyagarajan V, et al
    Impact of the indigenous rotavirus vaccine Rotavac in the Universal Immunization Program in India during 2016-2020.
    Nat Med. 2025 Oct 7. doi: 10.1038/s41591-025-03998.
    PubMed         Abstract available
    
    

    
    Pediatr Infect Dis J

26. OGIMI C, Ikuse T, Aizawa Y, Takanashi S, et al
    Current Challenges and Future Directions for RSV Prevention Strategies in Japan.
    Pediatr Infect Dis J. 2025;44:e400-e406.
    PubMed         Abstract available
    
    

    
    PLoS One

27. SMITH LM, Kartal T, Rawat S, Chaudhari A, et al
    Changes in free-roaming dog population demographics and health associated with a catch-neuter-vaccinate-release program in Jamshedpur, India.
    PLoS One. 2025;20:e0317636.
    PubMed         Abstract available
    
    

    
    Vaccine

28. HEINZE N, Martin AF, Tirion ASC, Pae R, et al
    Exploring the effectiveness of interventions to increase uptake of measles vaccination among healthcare workers: a systematic review.
    Vaccine. 2025;66:127808.
    PubMed         Abstract available
    
    
29. LEAKHENA PC, Awasthi S, Rabilloud M, Daw R, et al
    Pneumococcal colonization rates in children and adults in two developing countries: A prospective cross-sectional hospital-based study.
    Vaccine. 2025;64:127697.
    PubMed         Abstract available
    
    
30. SUN Y, Liu Y, Wang H, Guo Q, et al
    Immunogenicity and protection against infectious bursal disease via a transgenic Eimeria acervulina expressing IBDV VP2-2C3d fusion protein.
    Vaccine. 2025;64:127715.
    PubMed         Abstract available
    
    
31. KIM SH, Lee H, Wi YM, Cho UJ, et al
    Transmission dynamics and risk factors for pertussis during the 2023-2024 outbreak in Korea.
    Vaccine. 2025;64:127726.
    PubMed         Abstract available
    
    
32. ISLAM MD, Kurosu T, Okawa M, Morikoshi N, et al
    Trace amounts of cobalt serve as an adjuvant for unglycosylated JEV-ED3 expressed in E. coli, inducing a potent virus-neutralizing immune response.
    Vaccine. 2025;64:127742.
    PubMed         Abstract available
    
    
33. HARIT D, Sawant S, Spreng RL, Gurley S, et al
    Qualification of a reporter virus microneutralization assay for evaluation of influenza specific antibodies in human clinical trials.
    Vaccine. 2025;64:127699.
    PubMed         Abstract available
    
    
34. CHAKRABORTY S, Dutta P, Pal A, Chakraborty S, et al
    FliC adjuvant augments protective efficacy of recombinant T2544 antigen against SalmonellaTyphiand Paratyphi A by increasing serum antibodies, intestinal secretory immunoglobulin A and T cell memory.
    Vaccine. 2025;64:127767.
    PubMed         Abstract available
    
    
35. LEE YH, Gwak E, Kang HM, Choe YJ, et al
    Safety of intradermal Danish- vs. transcutaneous Tokyo-strain BCG vaccination in Korean children: A nationwide cohort study.
    Vaccine. 2025;65:127828.
    PubMed         Abstract available
    
    
36. ANDERSON KM, Nowak GJ, Cacciatore MA, Rohani P, et al
    Understanding influenza vaccination attitudes and behaviors: An assessment of health decision-making preferences.
    Vaccine. 2025;65:127804.
    PubMed         Abstract available
    
    
37. VAN SCHALKWYK C, Meyer-Rath G, Masuku S, Jamieson L, et al
    Corrigendum to "Cost-effectiveness of different HPV vaccination strategies for cervical cancer prevention in South Africa" [Vaccine 64 (2025) 127770].
    Vaccine. 2025;65:127797.
    PubMed        
    
    
38. PRAPATTANAKULLAWONG A, Sirisereewan C, Boonprakob R, Kamenkit O, et al
    Comparative evaluation of PRRSV MLV vaccine efficacy administered via intranasal and intramuscular routes in early age of piglets.
    Vaccine. 2025;65:127822.
    PubMed         Abstract available
    
    
39. JOHN FA, Criollo V, Gaghan C, Armwood AR, et al
    Recombinant Lactococcus lactis-based oral vaccine expressing non-toxic alpha toxin domains of Clostridium septicum can offer protection against Clostridial dermatitis in turkeys.
    Vaccine. 2025;65:127801.
    PubMed         Abstract available
    
    
40. ASHRAF M, Ghafoor A, Suleman M, Mukhtar M, et al
    Gamma-irradiated Salmonella Gallinarum oral vaccine elicits robust cellular and humoral immune responses in a chicken model.
    Vaccine. 2025;65:127833.
    PubMed         Abstract available
    
    
41. ROMANOVA J, Krokhin A, Ferko B, Pleimes D, et al
    Protective efficacy of the UniFluVec influenza vaccine vector against the highly pathogenic influenza A/Indonesia/5/2005 (H5N1) strain in ferrets.
    Vaccine. 2025;65:127795.
    PubMed         Abstract available
    
    
42. BRUCE AA, Gallagher K
    Determinants of measles second-dose vaccine coverage in the Gambia - a secondary analysis of 2019 demographic and health survey data.
    Vaccine. 2025;65:127789.
    PubMed         Abstract available
    
    
43. SHI N, Xiu S, Wang J, Shen Y, et al
    Subjective norms and perceived behavior control are more critical than attitudes in HPV vaccination: An investigation in China.
    Vaccine. 2025;65:127800.
    PubMed         Abstract available
    
    
44. LE T, Jia B, Sun C, Zhou Y, et al
    Lipid nanoparticle encapsulated membrane-anchored E2 mRNA vaccine elicits cross-protective immune responses against bovine viral diarrhoea virus infection in calves.
    Vaccine. 2025;66:127841.
    PubMed         Abstract available
    
    
45. HORA R, Ray A, Kumari A, Dutta M, et al
    Exploring the predictors for the uptake of Respiratory Syncytial Virus (RSV) vaccine under the immunization programme in India.
    Vaccine. 2025;66:127827.
    PubMed         Abstract available
    
    
46. SCHIEFERDECKER R, Menting T, Mankertz A, Santibanez S, et al
    Vaccination versus antibody screening for measles immunity in health care workers.
    Vaccine. 2025;66:127845.
    PubMed         Abstract available
    
    
47. HAYASHI T, Yao S, Sato-Kaneko F, Cozza R, et al
    Enhancing vaccine immunogenicity through heterologous prime-boost regimen with multiple nasal boosting with liposomal TLR7 ligand.
    Vaccine. 2025;65:127778.
    PubMed         Abstract available
    
    
48. KANG CK, Im YJ, Kim DY, Choe PG, et al
    Immunogenicity and safety evaluation of a recombinant protective antigen anthrax vaccine (GC1109): A phase II, dose-confirmed, randomized, double-blind, placebo-controlled study.
    Vaccine. 2025;65:127819.
    PubMed         Abstract available
    
    
49. HERNANDEZ M, Caltempa AO, Villalobos N, Elisondo MC, et al
    Novel Oral papaya-based preventive and therapeutic vaccine for controlling different zoonotic Taeniid parasites: Current advances.
    Vaccine. 2025;66:127818.
    PubMed         Abstract available
    
    
50. SHAMSRIZI P, Eitze S, Heinemeier D, Tanzer AS, et al
    Post-pandemic questions in vaccination counseling: Two qualitative analyses of open-ended responses comparing hypothetical and novel vaccines.
    Vaccine. 2025;66:127823.
    PubMed         Abstract available
    
    
51. ANGELIDOU A, Cotugno N, Sherman AC, Amodio D, et al
    Editorial for the special issue "Vaccines for the vulnerable".
    Vaccine. 2025;65:127783.
    PubMed        
    
    
52. EL HINDI T, Anugulruengkitt S, Lapphra K, Limkittikul K, et al
    Immunogenicity and safety of the live-attenuated tetravalent dengue vaccine (TAK-003) co-administered with recombinant 9-valent human papillomavirus vaccine.
    Vaccine. 2025 Oct 6:127786. doi: 10.1016/j.vaccine.2025.127786.
    PubMed         Abstract available
    
    
53. HALLIDAY R, Morais B, Bouaddi O, Deal A, et al
    Vaccine-preventable diseases in migrants in Europe: a systematic review.
    Vaccine. 2025;65:127788.
    PubMed         Abstract available
    
    
54. SCHOENFISCH C, Kauter K, Walz N, Wang T, et al
    Persistence of measles, mumps, and rubella immunity following childhood vaccination in Australian health science students: a cohort study.
    Vaccine. 2025;65:127791.
    PubMed         Abstract available
    
    
55. CLAY PA, Markowitz LE, Gopalani SV, Baxter A, et al
    HPV vaccination among gay, bisexual, and other men who have sex with men aged 27-45 years in the United States is potentially Cost-saving.
    Vaccine. 2025;65:127798.
    PubMed         Abstract available
    
    
56. LAING KJ, Sholukh AM, MacPhee KJ, McClurkan CL, et al
    Safety and immunogenicity of investigational herpes simplex virus-2 vaccines in adults with recurrent genital infection.
    Vaccine. 2025;65:127821.
    PubMed         Abstract available
    
    
57. ZOU Z, Hu Y, Yang H, Zhao M, et al
    Preferences and willingness-to-pay for human papillomavirus vaccination among men who have sex with men in China: a discrete choice experiment.
    Vaccine. 2025;65:127806.
    PubMed         Abstract available
    
    
58. JOHANSSON-LINDBOM B, Kitson G, Oostvogels L, Darsley M, et al
    Safety and immunogenicity of a single booster dose of the group B streptococcus AlpN candidate vaccine (GBS-AlpN) in previously vaccinated healthy women compared with a single dose in previously unvaccinated women.
    Vaccine. 2025;65:127820.
    PubMed         Abstract available
    
    
59. HIRAGA K, Momose H, Kuribayashi W, Uemura M, et al
    Development of a novel safety assessment method for quality control of mRNA vaccines based on lung biomarker gene expression.
    Vaccine. 2025;65:127805.
    PubMed         Abstract available
    
    
60. OGATA T, Hattori S, Kawachi K, Ishikane M, et al
    Durability of effectiveness of a booster dose of COVID-19 bivalent (ancestral/BA.4-5) vaccine against all-cause mortality in older adults in Japan, October 2022 to September 2023.
    Vaccine. 2025;65:127796.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.